STOCK TITAN

Trans American Aquaculture (OTC: GRPS) Q3 loss, no revenue reported in filing

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
10-Q

Rhea-AI Filing Summary

Trans American Aquaculture, Inc. reported continued operating losses and no shrimp revenue in its quarter ended September 30, 2025. For the three months, revenue was $0 and the net loss was $171,642, improving from a loss of $575,325 a year earlier mainly due to lower cost of goods sold and reduced legal, professional, and payroll expenses. For the nine months, revenue was also $0 versus $315,145 in 2024, with the net loss narrowing to $489,387 from $1,143,656.

The balance sheet shows a strained financial position, with current liabilities of $4,719,609 and current assets of $340,123, creating a working capital deficit of $4,379,486 and a stockholders’ deficit of $3,758,603. Cash was just $509 at quarter-end, and shareholders have loaned about $1,646,636 at double‑digit interest rates. The company exited Chapter 11 bankruptcy in October 2025 but still faces going concern uncertainty and is relying on GHS Investments equity financing and preferred stock and warrant issuances to fund operations. Common shares outstanding were 1,805,926,955 as of January 14, 2026.

Positive

  • None.

Negative

  • Severe liquidity and capital deficit: At September 30, 2025, current assets of $340,123 versus current liabilities of $4,719,609 produced a working capital deficit of $4,379,486, alongside a stockholders’ deficit of $3,758,603 and cash of just $509.
  • No operating revenue in 2025 year-to-date: The company reported $0 revenue for both the three‑ and nine‑month periods ended September 30, 2025, compared with $315,145 for the prior‑year nine‑month period, while continuing to incur operating losses.
  • Going concern uncertainty and high-cost debt: Management explicitly states substantial doubt about the company’s ability to continue as a going concern, citing dependence on new capital, related‑party notes of approximately $1,646,636 at 12–18% interest, and the need to renegotiate or extend these obligations.
  • Bankruptcy history and asset loss: The company filed for Chapter 11 in December 2024 following a deed in lieu of foreclosure on key farm property; although the case was dismissed on October 28, 2025, the episode underscores prior financial distress and the loss of that secured property.
  • Significant potential dilution from GHS financings: Multiple Securities Purchase Agreements and Equity Financing Agreements with GHS involve issuances of Series D Preferred Stock and very large warrant packages, such as 306,666,667 warrants at $0.000115 exercise price and 71,250,000 warrants at $0.000345, which could materially dilute existing common shareholders if fully exercised.

Insights

Q3 2025 shows severe liquidity stress, no revenue, and heavy reliance on high-cost capital.

Trans American Aquaculture posted no shrimp revenue in Q3 or the first nine months of 2025, versus $315,145 for the comparable 2024 period. The nine‑month net loss narrowed to $489,387, helped by sharply lower cost of goods sold and reduced general and administrative expenses, but the business is not generating operating cash. Operating cash outflow was $771,113 over nine months.

The balance sheet highlights acute stress: current assets of $340,123 versus current liabilities of $4,719,609 create a working capital deficit of $4,379,486, and stockholders’ deficit stands at $3,758,603. Cash was only $509, while shareholders have advanced roughly $1,646,636 in notes at 12–18% interest. The company previously filed Chapter 11 in December 2024; that case was dismissed on October 28, 2025, but the going concern note emphasizes that continued operations depend on raising additional capital and executing its shrimp production plan.

To fund itself, the company has entered multiple arrangements with GHS Investments, including two Equity Financing Agreements each permitting up to $10,000,000 of common stock purchases at a discount to market, and several Securities Purchase Agreements for Series D Preferred Stock plus large blocks of warrants (for example, 306,666,667 warrants at a $0.000115 exercise price under the March 2025 SPA). These structures provide fundraising flexibility but imply significant potential dilution for existing common shareholders if utilized extensively.

false --12-31 2025 Q3 0001990446 0001990446 2025-01-01 2025-09-30 0001990446 2026-01-14 0001990446 2025-09-30 0001990446 2024-12-31 0001990446 us-gaap:SeriesAPreferredStockMember 2025-09-30 0001990446 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001990446 us-gaap:SeriesBPreferredStockMember 2025-09-30 0001990446 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001990446 us-gaap:SeriesCPreferredStockMember 2025-09-30 0001990446 us-gaap:SeriesCPreferredStockMember 2024-12-31 0001990446 us-gaap:SeriesDPreferredStockMember 2025-09-30 0001990446 us-gaap:SeriesDPreferredStockMember 2024-12-31 0001990446 2025-07-01 2025-09-30 0001990446 2024-07-01 2024-09-30 0001990446 2024-01-01 2024-09-30 0001990446 us-gaap:CapitalUnitsMember 2023-12-31 0001990446 us-gaap:CommonStockMember 2023-12-31 0001990446 GRPS:PreferredStockSeriesAMember 2023-12-31 0001990446 GRPS:PreferredStockSeriesBMember 2023-12-31 0001990446 GRPS:PreferredStockSeriesCMember 2023-12-31 0001990446 GRPS:PreferredStockSeriesDMember 2023-12-31 0001990446 GRPS:SharesToBeIssuedMember 2023-12-31 0001990446 us-gaap:RetainedEarningsMember 2023-12-31 0001990446 2023-12-31 0001990446 us-gaap:CapitalUnitsMember 2024-03-31 0001990446 us-gaap:CommonStockMember 2024-03-31 0001990446 GRPS:PreferredStockSeriesAMember 2024-03-31 0001990446 GRPS:PreferredStockSeriesBMember 2024-03-31 0001990446 GRPS:PreferredStockSeriesCMember 2024-03-31 0001990446 GRPS:PreferredStockSeriesDMember 2024-03-31 0001990446 GRPS:SharesToBeIssuedMember 2024-03-31 0001990446 us-gaap:RetainedEarningsMember 2024-03-31 0001990446 2024-03-31 0001990446 us-gaap:CapitalUnitsMember 2024-06-30 0001990446 us-gaap:CommonStockMember 2024-06-30 0001990446 GRPS:PreferredStockSeriesAMember 2024-06-30 0001990446 GRPS:PreferredStockSeriesBMember 2024-06-30 0001990446 GRPS:PreferredStockSeriesCMember 2024-06-30 0001990446 GRPS:PreferredStockSeriesDMember 2024-06-30 0001990446 GRPS:SharesToBeIssuedMember 2024-06-30 0001990446 us-gaap:RetainedEarningsMember 2024-06-30 0001990446 2024-06-30 0001990446 us-gaap:CapitalUnitsMember 2024-12-31 0001990446 us-gaap:CommonStockMember 2024-12-31 0001990446 GRPS:PreferredStockSeriesAMember 2024-12-31 0001990446 GRPS:PreferredStockSeriesBMember 2024-12-31 0001990446 GRPS:PreferredStockSeriesCMember 2024-12-31 0001990446 GRPS:PreferredStockSeriesDMember 2024-12-31 0001990446 GRPS:SharesToBeIssuedMember 2024-12-31 0001990446 us-gaap:RetainedEarningsMember 2024-12-31 0001990446 us-gaap:CapitalUnitsMember 2025-03-31 0001990446 us-gaap:CommonStockMember 2025-03-31 0001990446 GRPS:PreferredStockSeriesAMember 2025-03-31 0001990446 GRPS:PreferredStockSeriesBMember 2025-03-31 0001990446 GRPS:PreferredStockSeriesCMember 2025-03-31 0001990446 GRPS:PreferredStockSeriesDMember 2025-03-31 0001990446 GRPS:SharesToBeIssuedMember 2025-03-31 0001990446 us-gaap:RetainedEarningsMember 2025-03-31 0001990446 2025-03-31 0001990446 us-gaap:CapitalUnitsMember 2025-06-30 0001990446 us-gaap:CommonStockMember 2025-06-30 0001990446 GRPS:PreferredStockSeriesAMember 2025-06-30 0001990446 GRPS:PreferredStockSeriesBMember 2025-06-30 0001990446 GRPS:PreferredStockSeriesCMember 2025-06-30 0001990446 GRPS:PreferredStockSeriesDMember 2025-06-30 0001990446 GRPS:SharesToBeIssuedMember 2025-06-30 0001990446 us-gaap:RetainedEarningsMember 2025-06-30 0001990446 2025-06-30 0001990446 us-gaap:CapitalUnitsMember 2024-01-01 2024-03-31 0001990446 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001990446 GRPS:PreferredStockSeriesAMember 2024-01-01 2024-03-31 0001990446 GRPS:PreferredStockSeriesBMember 2024-01-01 2024-03-31 0001990446 GRPS:PreferredStockSeriesCMember 2024-01-01 2024-03-31 0001990446 GRPS:PreferredStockSeriesDMember 2024-01-01 2024-03-31 0001990446 GRPS:SharesToBeIssuedMember 2024-01-01 2024-03-31 0001990446 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001990446 2024-01-01 2024-03-31 0001990446 us-gaap:CapitalUnitsMember 2024-04-01 2024-06-30 0001990446 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001990446 GRPS:PreferredStockSeriesAMember 2024-04-01 2024-06-30 0001990446 GRPS:PreferredStockSeriesBMember 2024-04-01 2024-06-30 0001990446 GRPS:PreferredStockSeriesCMember 2024-04-01 2024-06-30 0001990446 GRPS:PreferredStockSeriesDMember 2024-04-01 2024-06-30 0001990446 GRPS:SharesToBeIssuedMember 2024-04-01 2024-06-30 0001990446 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001990446 2024-04-01 2024-06-30 0001990446 us-gaap:CapitalUnitsMember 2024-07-01 2024-09-30 0001990446 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001990446 GRPS:PreferredStockSeriesAMember 2024-07-01 2024-09-30 0001990446 GRPS:PreferredStockSeriesBMember 2024-07-01 2024-09-30 0001990446 GRPS:PreferredStockSeriesCMember 2024-07-01 2024-09-30 0001990446 GRPS:PreferredStockSeriesDMember 2024-07-01 2024-09-30 0001990446 GRPS:SharesToBeIssuedMember 2024-07-01 2024-09-30 0001990446 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001990446 us-gaap:CapitalUnitsMember 2025-01-01 2025-03-31 0001990446 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001990446 GRPS:PreferredStockSeriesAMember 2025-01-01 2025-03-31 0001990446 GRPS:PreferredStockSeriesBMember 2025-01-01 2025-03-31 0001990446 GRPS:PreferredStockSeriesCMember 2025-01-01 2025-03-31 0001990446 GRPS:PreferredStockSeriesDMember 2025-01-01 2025-03-31 0001990446 GRPS:SharesToBeIssuedMember 2025-01-01 2025-03-31 0001990446 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001990446 2025-01-01 2025-03-31 0001990446 us-gaap:CapitalUnitsMember 2025-04-01 2025-06-30 0001990446 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001990446 GRPS:PreferredStockSeriesAMember 2025-04-01 2025-06-30 0001990446 GRPS:PreferredStockSeriesBMember 2025-04-01 2025-06-30 0001990446 GRPS:PreferredStockSeriesCMember 2025-04-01 2025-06-30 0001990446 GRPS:PreferredStockSeriesDMember 2025-04-01 2025-06-30 0001990446 GRPS:SharesToBeIssuedMember 2025-04-01 2025-06-30 0001990446 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001990446 2025-04-01 2025-06-30 0001990446 us-gaap:CapitalUnitsMember 2025-07-01 2025-09-30 0001990446 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001990446 GRPS:PreferredStockSeriesAMember 2025-07-01 2025-09-30 0001990446 GRPS:PreferredStockSeriesBMember 2025-07-01 2025-09-30 0001990446 GRPS:PreferredStockSeriesCMember 2025-07-01 2025-09-30 0001990446 GRPS:PreferredStockSeriesDMember 2025-07-01 2025-09-30 0001990446 GRPS:SharesToBeIssuedMember 2025-07-01 2025-09-30 0001990446 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001990446 us-gaap:CapitalUnitsMember 2024-09-30 0001990446 us-gaap:CommonStockMember 2024-09-30 0001990446 GRPS:PreferredStockSeriesAMember 2024-09-30 0001990446 GRPS:PreferredStockSeriesBMember 2024-09-30 0001990446 GRPS:PreferredStockSeriesCMember 2024-09-30 0001990446 GRPS:PreferredStockSeriesDMember 2024-09-30 0001990446 GRPS:SharesToBeIssuedMember 2024-09-30 0001990446 us-gaap:RetainedEarningsMember 2024-09-30 0001990446 2024-09-30 0001990446 us-gaap:CapitalUnitsMember 2025-09-30 0001990446 us-gaap:CommonStockMember 2025-09-30 0001990446 GRPS:PreferredStockSeriesAMember 2025-09-30 0001990446 GRPS:PreferredStockSeriesBMember 2025-09-30 0001990446 GRPS:PreferredStockSeriesCMember 2025-09-30 0001990446 GRPS:PreferredStockSeriesDMember 2025-09-30 0001990446 GRPS:SharesToBeIssuedMember 2025-09-30 0001990446 us-gaap:RetainedEarningsMember 2025-09-30 0001990446 2022-08-28 0001990446 us-gaap:SeriesAPreferredStockMember GRPS:MrGouldingMember 2022-08-27 2022-08-28 0001990446 us-gaap:CommonStockMember GRPS:MrGouldingMember 2022-08-27 2022-08-28 0001990446 us-gaap:LandImprovementsMember 2025-09-30 0001990446 us-gaap:BuildingAndBuildingImprovementsMember 2025-09-30 0001990446 GRPS:FarmEquipmentMember srt:MinimumMember 2025-09-30 0001990446 srt:MaximumMember GRPS:FarmEquipmentMember 2025-09-30 0001990446 us-gaap:VehiclesMember 2025-09-30 0001990446 2020-01-01 2020-12-31 0001990446 2020-12-31 0001990446 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember GRPS:OneCustomerMember 2025-01-01 2025-09-30 0001990446 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember GRPS:OneCustomerMember 2024-01-01 2024-09-30 0001990446 GRPS:SecuritiesPurchaseAgreementsGHSMember us-gaap:SeriesDPreferredStockMember 2025-12-01 2025-12-02 0001990446 GRPS:AccountsReceivableFactoringAgreementMember 2023-12-11 0001990446 GRPS:AccountsReceivableFactoringAgreementMember 2023-12-10 2023-12-11 0001990446 GRPS:AccountsReceivableFactoringAgreementMember 2024-02-07 0001990446 GRPS:AccountsReceivableFactoringAgreementMember 2025-01-01 2025-09-30 0001990446 GRPS:AccountsReceivableFactoringAgreementMember 2024-01-01 2024-09-30 0001990446 GRPS:BroodstockAnimalsMember 2025-09-30 0001990446 GRPS:BroodstockAnimalsMember 2024-09-30 0001990446 GRPS:ShrimpMember 2025-09-30 0001990446 GRPS:ShrimpMember 2024-09-30 0001990446 GRPS:BroodstockMember 2025-09-30 0001990446 GRPS:BroodstockMember 2024-09-30 0001990446 GRPS:BroodstockRestockingMember 2025-09-30 0001990446 GRPS:BroodstockRestockingMember 2024-09-30 0001990446 us-gaap:VehiclesMember 2024-09-30 0001990446 us-gaap:BuildingImprovementsMember 2025-09-30 0001990446 us-gaap:BuildingImprovementsMember 2024-09-30 0001990446 GRPS:FarmEquipmentMember 2025-09-30 0001990446 GRPS:FarmEquipmentMember 2024-09-30 0001990446 us-gaap:OtherMachineryAndEquipmentMember 2025-09-30 0001990446 us-gaap:OtherMachineryAndEquipmentMember 2024-09-30 0001990446 GRPS:NoteToFormerOwnerOfFarmPropertyMember 2025-09-30 0001990446 GRPS:NoteToFormerOwnerOfFarmPropertyMember 2025-01-01 2025-09-30 0001990446 GRPS:PromissoryNoteMember 2025-09-30 0001990446 GRPS:PromissoryNoteMember 2025-01-01 2025-09-30 0001990446 GRPS:PromissoryNote1Member 2025-09-30 0001990446 GRPS:PromissoryNote1Member 2025-01-01 2025-09-30 0001990446 GRPS:SecuredNoteMember 2025-01-01 2025-09-30 0001990446 GRPS:NoteToBankInterestMember 2025-09-30 0001990446 GRPS:NoteToBankInterestMember 2025-01-01 2025-09-30 0001990446 GRPS:UnsecuredPromissoryNoteMember 2024-02-29 0001990446 GRPS:UnsecuredPromissoryNoteMember 2024-02-01 2024-02-29 0001990446 GRPS:SecuredPromissoryNoteMember 2024-05-31 0001990446 GRPS:SecuredPromissoryNoteMember 2024-05-01 2024-05-31 0001990446 GRPS:UnsecuredPromissoryNoteMember 2024-08-31 0001990446 GRPS:UnsecuredPromissoryNoteMember 2024-08-01 2024-08-31 0001990446 GRPS:NoteToFormerOwnerOfFarmPropertyMember 2024-09-30 0001990446 GRPS:PromissoryNoteMember 2024-09-30 0001990446 GRPS:PromissoryNote1Member 2024-09-30 0001990446 GRPS:SecuredNoteMember 2025-09-30 0001990446 GRPS:SecuredNoteMember 2024-09-30 0001990446 GRPS:NoteToBankInterestMember 2024-09-30 0001990446 GRPS:ShareholdersMember 2025-09-30 0001990446 GRPS:ShareholdersMember srt:MinimumMember 2025-01-01 2025-09-30 0001990446 GRPS:ShareholdersMember srt:MaximumMember 2025-01-01 2025-09-30 0001990446 GRPS:ShareholdersMember 2024-09-30 0001990446 2024-02-27 0001990446 2024-02-26 2024-02-27 0001990446 2024-05-29 0001990446 2024-05-28 2024-05-29 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-01-19 2023-01-20 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-01-20 0001990446 GRPS:SecuritiesPurchaseAgreementsMember 2023-01-20 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-04-17 2023-04-18 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-04-18 0001990446 GRPS:SecuritiesPurchaseAgreementsMember 2023-04-18 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-05-21 2023-05-22 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-05-22 0001990446 GRPS:SecuritiesPurchaseAgreementsMember 2023-05-22 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-07-05 2023-07-06 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-07-06 0001990446 GRPS:SecuritiesPurchaseAgreementsMember 2023-07-06 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-09-25 2023-09-26 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2023-09-26 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember GRPS:Tranche1Member 2023-09-25 2023-09-26 0001990446 GRPS:SecuritiesPurchaseAgreementsMember 2023-09-26 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember GRPS:Tranche2Member 2023-10-11 2023-10-12 0001990446 GRPS:SecuritiesPurchaseAgreementsMember 2023-10-12 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2025-03-27 2025-03-28 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2025-03-28 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember GRPS:Tranche1Member 2025-03-27 2025-03-28 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember GRPS:Tranche1Member 2025-03-28 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember GRPS:PurchaseOfFifteenSharesMember 2025-03-27 2025-03-28 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember GRPS:PurchaseOfFiftyThreeSharesMember 2025-03-27 2025-03-28 0001990446 GRPS:SecuritiesPurchaseAgreementsMember 2025-03-31 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2025-04-01 2025-04-02 0001990446 GRPS:SecuritiesPurchaseAgreementsMember GRPS:WarrantsMember 2025-04-02 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2025-06-17 2025-06-18 0001990446 GRPS:SecuritiesPurchaseAgreementsMember GRPS:WarrantsMember 2025-06-18 0001990446 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-09-30 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2025-09-17 2025-09-18 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember 2025-09-18 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember GRPS:Tranche1Member 2025-09-17 2025-09-18 0001990446 GRPS:SecuritiesPurchaseAgreementsMember us-gaap:SeriesDPreferredStockMember GRPS:Tranche1Member 2025-09-18 0001990446 GRPS:SecuritiesPurchaseAgreementsMember 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure GRPS:Integer

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the quarterly period ended September 30, 2025

 

Or

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the transition period from ________________ to ________________

 

Commission File Number: 000-56640

 

TRANS AMERICAN AQUACULTURE, INC.

(Exact name of registrant as specified in its charter)

 

Colorado   02-0685828
(State of other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
1022 Shadyside Lane, Dallas, TX   75223
(Address of Principal Executive Offices)   (Zip Code)

 

(972) 358-6037

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Not applicable   Not applicable   Not applicable

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

The number of shares of the registrant’s common stock, $0.000001 par value per share, outstanding as of January 14, 2026, was 1,805,926,955.

 

 

 

   

 

 

TABLE OF CONTENTS

 

 

PART I—FINANCIAL INFORMATION 3
Item 1. Financial Statements 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19
Item 3. Quantitative and Qualitative Disclosures About Market Risk 24
Item 4. Controls and Procedures 24
PART II—OTHER INFORMATION 25
Item 1. Legal Proceedings 25
Item 5. Other Information 25
Item 6. Exhibits 25
SIGNATURES 26

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Balance Sheets

 

           
   Unaudited   
   September 30,  December 31,
ASSETS  2025  2024
       
CURRENT ASSETS          
Cash and cash equivalents  $509   $0 
Other receivable   0    26,480 
Inventory   338,898    230,830 
Other Assets   716    0 
TOTAL CURRENT ASSETS   340,123    257,310 
           
PROPERTY AND EQUIPMENT   1,237,992    1,237,992 
Less accumulated depreciation   (471,429)   (547,287)
NET PROPERTY AND EQUIPMENT   766,564    690,705 
           
           
TOTAL ASSETS  $1,106,686   $948,015 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
CURRENT LIABILITIES          
Bank overdraft  $0   $1,000 
Accounts payable   751,883    530,776 
Accrued interest expense   850,388    114,568 
Other accrued expenses   981,417    753,870 
Income tax payable   0    0 
Related parties notes   1,459,343    1,646,636 
Current portion of notes payable   676,577    562,063 
TOTAL CURRENT LIABILITIES   4,719,609    3,608,912 
           
LONG-TERM LIABILITIES          
Notes payable, net of current portion   145,680    561,087 
Deferred tax liability, net   0    0 
TOTAL LONG-TERM LIABILITIES   145,680    561,087 
           
STOCKHOLDERS' (DEFICIT) EQUITY          
Common stock, $.000001 par value, 6,000,000,000 shares authorized, 1,805,926,955 and 1,805,926,955 shares issued and outstanding   0    0 
Preferred Stock, Series A, .000001 par value 9,078,000 and 9,078,000 shares authorized, 9,078,000 issued and outstanding   0    0 
Preferred Stock, Series B, .000001 par value 5,000 and 5,000 shares authorized, 5,000 issued and outstanding   0    0 
Preferred Stock, Series C, $.000001 par value, 100,000 and 100,000 shares authorized, 100,000 issued and outstanding   0    0 
Preferred Stock, Series C to be issued   (195,721)   0 
Preferred Stock, Series D, .000001 par value, 1,295 shares authorized, 1,193 and 1,193 issued and outstanding   0    0 
Additional paid in capital - common stock   121,118    99,980 
Additional paid in capital - preferred stock (Series C)   1,287,091    1,317,467 
Additional paid in capital - preferred stock (Series D)   1,193,863    1,036,135 
Accumulated deficit   (6,164,954)   (5,675,567)
TOTAL STOCKHOLDERS' (DEFICIT) EQUITY   (3,758,603)   (3,221,985)
           
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $1,106,686   $948,014 

 

The accompanying notes are an integral part of these financial statements.

 

 3 

 

 

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Statements of Operations

Unaudited

 

                     
   For the three Months ended  For the 9 months Months ended
   September 30,  September 30,
   2025  2024  2025  2024
             
REVENUES                    
Sales and service  $0   $0   $0   $315,145 
                     
COST OF REVENUES                    
Cost of revenues   0    196,552    0    419,851 
                     
GROSS MARGIN   0    (196,552)   0    (104,706)
                     
GENERAL AND ADMINISTRATIVE EXPENSES   83,396    213,250    266,357    534,633 
                     
OTHER INCOME (EXPENSE)                    
Other income   0    11,041    918    11,741 
Other expense   0    (728)   (8,420)   (66,702)
Interest expense   (88,246)   (175,836)   (215,528)   (449,356)
                     
TOTAL OTHER INCOME (EXPENSE)   (88,246)   (165,523)   (223,030)   (504,317)
                     
NET INCOME (LOSS) BEFORE TAXES   (171,642)   (575,325)   (489,387)   (1,143,656)
                     
INCOME TAX (EXPENSE) BENEFIT   0    0    0    0 
                     
NET INCOME (LOSS)  $(171,642)  $(575,325)  $(489,387)  $(1,143,656)
                     
Basic and Diluted Net loss per common share   (0.000095)   (0.000328)   (0.000271)   (0.000378
                     
Weighted average common shares outstanding - basic   1,805,926,955    1,471,954,105    1,805,926,955    1,464,204,910 

 

The accompanying notes are an integral part of these financial statements.

 

 

 

 4 

 

 

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Statements of Stockholders' Equity

For the nine months ended September 30, 2024 and 2025

 

                                                                 
   Members'  Common Stock  Preferred Stock, Series A  Preferred Stock, Series B  Preferred Stock, Series C  Preferred Stock, Series D  Shares to be issued  Accumulated    
   Capital  Shares   Amount  Shares   Amount  Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Deficit    Total  
Balance December 31, 2023  $0  1,452,655,528   $100,000   9,078,000   $0   5,000  $0   100,000  $1,287,091   1,076  $1,076,863   0  $0   $(2,943,231)  $(479,277)
                                                                 
Issuance of common shares   0  0    0    0    0   0   0   0   0   0   0   0   0    0    0 
Issuance of preferred shares   0  0    0   0    0   0   0   0   0      0    0   0    0     0 
Stock Dividends   0  0    0   0    0   0   0   0   0   0   0   0   0    0    0 
Net loss   0  0    0   0    0   0   0   0   0   0   0   0   0    (238,021)   (238,021)
Balance March 31, 2024  $0  1,452,655,528   $100,000   9,078,000   $0   5,000  $0   100,000  $1,287,091   1,076  $1,076,863   0  $0   $(3,203,032)  $(717,298)
                                                                 
Issuance of common shares   0  0   $0   0    0   0   0   0   0   0   0   0   0    0    0 
Issuance of preferred shares   0  0    0   0    0   0   0   0   0   0   22,213   0   0    (22,213)   0 
Stock Dividends   0  0    0   0    0   0   0   0   0   0   0   0   0    0    0 
Net loss   0  0    0   0    0   0   0   0   0   0   0   0   0    (330,311)   (330,311)
Balance June 30, 2024  $0  1,452,655,528   $100,000   9,078,000   $0   5,000  $0   100,000  $1,287,091   1,076  $1,099,076   0  $0   $(3,555,556)  $(1,047,609)
                                                                 
Issuance of common shares   0  0    0   0    0   0   0   0   0   0   0   0   0    0    0 
Issuance of preferred shares   0  0    0   0    0   0   0   0   0   0   0   0   0    (22,915)   (22,915)
Stock Dividends   0  0    0   0    0   0   0   0   0   0   0   0   0        0 
Net loss   0  0    0   0    0   0   0   0   0   0   0   0   0    (575,325)   (575,325)
Balance September 30, 2024  $0  1,452,655,528   $100,000   9,078,000   $0   5,000  $0   100,000  $1,287,091   1,076  $1,099,076   0  $0   $(4,153,796)  $(1,645,849)

(continued)

 

 

 5 

 

 

   Members'  Common Stock  Preferred Stock, Series A  Preferred Stock, Series B  Preferred Stock, Series C  Preferred Stock, Series D  Shares to be issued  Accumulated    
   Capital  Shares  Amount  Shares   Amount  Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Deficit    Total  
                                                                
Balance December 31, 2024  $0  1,805,926,955  $100,000   9,078,000   $0   5,000  $0   100,000  $1,287,091   1,076  $1,076,863     $   $(5,675,567)  $(3,221,985)
                                                                
Issuance of common shares   0     21,118   0    0   0   0   0   0   0   0   0   0    0    0 
                                                                
Issuance of preferred shares   0  0   0   0    0   0   0   0   0   30   33,000   0   0    0    33,000 
                                                                
Stock Dividends   0  0   0   0    0   0   0   0   0   0   0   0   0    0    0 
                                                                
Net loss   0  0   0   0    0   0   0   0   0   0   0   0   0    (113,707)   (113,707)
                                                                
Balance March 31, 2025  $0  1,805,926,955  $121,118   9,078,000   $0   5,000  $0   100,000  $1,287,091   1,106  $1,109,863   0  $0   $(5,789,274)  $(3,302,692)
                                                                
Issuance of common shares   0         0    0   0   0   0   0   0   0   0   0    0    0 
                                                                
Issuance of preferred shares   0  0   0   0    0   0   0   0   0   43   40,000   0   (283,967)   0    (212,477)
                                                                
Stock Dividends   0  0   0   0    0   0   0   0   0   0   0   0   0    0    0 
                                                                
Net loss   0  0   0   0    0   0   0   0   0   0   0   0   0    (204,038)   (204,038)
                                                                
Balance June 30, 2025  $0  1,805,926,955  $121,118   9,078,000   $0   5,000  $0   100,000  $1,287,091   1,149  $1,149,863   0  $(283,967)  $(5,993,312)  $(3,719,207)
                                                                
Issuance of common shares   0  0       0    0   0   0   0   0   0   0   0   0    0    0 
                                                                
Issuance of preferred shares   0  0   0   0    0   0   0   0   0   47   44,000   0   88,246    0    132,246 
                                                                
Stock Dividends   0  0   0   0    0   0   0   0   0   0   0   0   0    0    0 
                                                                
Net loss   0  0   0   0    0   0   0   0   0   0   0   0   0    (171,642)   (171,642)
                                                                
Balance September 30, 2025  $0  1,805,926,955  $121,118   9,078,000   $0   5,000  $0   100,000  $1,287,091   1,196  $1,193,863   0  $(195,721)  $(6,164,954)  $(3,758,603)

 

The accompanying notes are an integral part of these financial statements.

 

 

 

 6 

 

 

 

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Statements of Cash Flows

 

           
   Unaudited  Unaudited
   For the 9 months ending
   September 30,
   2025  2024
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(489,387)  $(1,143,656)
Noncash items included in net loss:          
Depreciation expense   4,865    52,291 
Common stock issued for professional services and other non cash items   0    17,371 
(Increase) decrease in:          
Other receivable   12,794    (12,357)
Inventory   (110,546)   25,591 
Deferred taxes   0    0 
Other assets   0    (904)
Increase (decrease) in:          
Accounts payable and other accrued expenses   (835,244)   254,607 
Income tax payable   0    0 
Accrued interest expense   646,403    364,861 
CASH USED IN OPERATING ACTIVITIES   (771,113)   (442,196)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Cash paid for the purchase of fixed assets   0    (12,216)
Accumulated Depreciation   21,232    19,710 
CASH USED IN INVESTING ACTIVITIES   21,232    7,494 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payment of bank overdraft   (1,000)   0 
Bank overdraft   0    5,605 
Proceeds from shareholder notes payable   0    48,988 
Payments on shareholder notes payable   (216)   (74,375)
Payments on notes payable       (74,243)
Proceeds from on related party notes payable   627,912    506,000 
Payments due to related parties   0    16,127 
Contributions   0    0 
Stock Dividends   0    0 
Issuance of Preferred Shares   117,000    0 
CASH PROVIDED BY FINANCING ACTIVITIES   743,696    428,102 
           
NET INCREASE (DECREASE)   (6,185)   (6,600)
           
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD   6,694    6,600 
           
CASH AND CASH EQUIVALENTS AT END OF PERIOD  $509   $0 
           
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid for interest  $0   $84,496 
Cash paid for income taxes  $0   $0 
           
NON-CASH          
Preferred series D stock dividends  $0   $66,910 
Common stock issued for services rendered  $0   $19,012 
Capitalization of related party member notes to members' capital  $0   $0 

 

The accompanying notes are an integral part of these financial statements.

 

 

 

 7 

 

 

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Notes to Consolidated Financial Statements

September 30, 2025 and September 30, 2024

 

 

NOTE 1 – BUSINESS ORGANIZATION

 

Business Organization

 

Trans American Aquaculture, Inc. formerly Gold River Productions, Inc. (GRP), (“the Company”) was incorporated in the State of Delaware on September 18, 2006, as Polythene Metro Corp before being acquired by Gold River Productions, Inc. on January 25, 2007. The Company was re-incorporated in the State of Colorado in July 2018. In February 2023, pursuant to shareholder and Board approval, the Company changed its name to Trans American Aquaculture, Inc., reflective of its new management and operations, and applied to the Financial Industry Regulatory Authority (“FINRA”) to change its ticker symbol from GRPS to TAAQ.

 

On August 28, 2022, Richard Goulding, executive and selling party of Gold River Productions, Inc. and Adam Thomas, purchaser, executed a Stock Purchase Agreement (“SPA”).  Under the terms of the SPA, Mr.  Goulding, agreed to sell to Adam Thomas, CEO of TAA, 9,078,000 shares of the Company’s Series A Preferred Stock, and to retain 640,000 shares for later conversion to the Company’s common stock.  Each share of Series A Preferred Stock is convertible into 100 shares of the Company’s common stock.  In addition, Mr. Thomas agreed to purchase all the Company’s outstanding shares of Series B Preferred Stock from Mr. Goulding for a cash payment of $5,000.

 

In further consideration for the sale of the shares of Series A and Series B Preferred Stock, Mr. Goulding agreed to:

 

1. Increase the authorized shares of the Company’s common stock to three billion (3,000,000,000) shares;

 

2. Convert his retained 640,000 shares of Series A Preferred Stock, to 64,000,000 shares of common stock;

 

3. Issue to various former employees and consultants of the Company an aggregate amount of 15,248,503 shares of the Company’s common stock; and

 

4. Complete the assignment of assets and assumption of liabilities as they existed immediately prior to the closing of the stock purchase agreement on August 29, 2022.

 

Following the purchase of the shares of Class A and Class B Preferred Stock, Mr. Thomas and TAA agreed to:

 

1. To have the Company issue shares of a Class C Preferred Stock to the former members of TAA, such shares to be convertible into 85% of the Company’s common stock, but limited as to this conversion for a minimum of 12 months from the date of issuance; and

 

2. To cancel and withdraw the shares of Series A Preferred Stock.

 

On August 29, 2022, Gold River Productions, Inc. and Goulding executed an Assignment of Rights and Assumption of Liabilities Agreement whereby Gold River Productions, Inc. assigned all of its assets and liabilities to Mr. Richard Goulding (Mr. Goulding), Chairman of the Board and CEO of GRP, resulting in GRP becoming a public shell company without any assets or liabilities and became the accounting acquiree.

 

 

 

 8 

 

 

On September 13, 2022, Gold River Productions, Inc. and Trans American Aquaculture, LLC (“TAA”) executed a Definitive Equity Exchange Agreement in a transaction accounted for as a reverse acquisition, whereby TAA became the accounting acquiror. TAA operates a large land-based shrimp farming and technology company located in South Texas. The Company produces premium quality, farm-raised white shrimp, 100% free of antibiotics and hormones, and cultivated using safe and sustainable practices. Its principal markets consist of seafood distributors, restaurants, and grocery store chains in the United States. Using decades of experience in the shrimp aquaculture industry, products are grown with our superior technology and our proprietary genetics which results in a superior fresh product always grown in the United States.

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Accounting

 

The accompanying consolidated financial statements include the accounts of Trans American Aquaculture, Inc. and its wholly owned subsidiary Trans American Aquaculture, LLC, a Texas Limited Liability Company. All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying financial statements have been prepared on the accrual basis of accounting.

 

Cash and Cash Equivalents

 

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents.

 

Inventory

 

Inventory is valued at lower of cost or the net realizable value on a first-in, first-out basis. Depending on the development and growth stage of shrimp, the Company’s inventory is comprised of 1) broodstock held for restocking the next harvest cycle, 2) broodstock held for sale, and shrimp held for sale. The Company evaluates realization of shrimp based on market prices at the end of each period.

 

Property and Equipment

 

Property and equipment are stated at cost. Maintenance and repairs are expensed while expenditures for renewals which prolong the lives of the assets are capitalized. When items are disposed of, the cost and accumulated depreciation are eliminated from the accounts and any net gain or loss is included in the consolidated statement of income.

 

For financial reporting purposes, depreciation of property and equipment is provided for by using the straight-line method based on the estimated service lives of the property as follows:

 
Land improvements 40 years
Buildings and structures 40 years
Farm equipment 10 – 20 years
Autos and trucks 10 years

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that an asset has been impaired, the amount of the impairment is charged to operations. No impairments were recognized for the periods ended September 30, 2025 and 2024.

 

 

 

 9 

 

 

Income Taxes

 

The Company uses an asset and liability approach to financial accounting and reporting for income taxes. The difference between the financial statement and tax basis of assets and liabilities is determined annually.

 

Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the periods in which they are expected to affect taxable income. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. Income tax expense is the current tax payable or refundable for the period, plus or minus the net change in the deferred tax assets and liabilities.

 

The Company’s income tax returns are subject to examination by the appropriate tax jurisdictions. As of September 30, 2025, the Company needs to file federal and state income tax returns for 2020, 2021, 2022, 2023 and 2024. During 2020, the Company had taxable income primarily as a result of a short-term capital gain of $445,500 on the sale of a joint venture interest. This resulted in taxable income of $155,200 and an unremitted federal income tax liability of $33,180. With accrued penalties and interest, the total due the IRS is approximately $58,300. All liabilities, including federal taxes, were indemnified by Goulding as part of the transaction and accordingly a receivable due from the previous owner of the Company has been recorded and netted against the tax obligation. The Company intends to file its 2020 federal tax return and pay the tax due, plus penalties in interest once it has sufficient cash to do so.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

 

Revenue Recognition

 

The Company recognizes revenues according to the Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC 606”) and Accounting Standard Update ASU 2014-09 “Revenues from Contracts with Customers.” Under the ASC 606, revenues is recognized when the customer obtains control of promised goods or services in amounts that reflect the consideration which the entity expected to receive in exchange of goods and service. The Company does not collect sales, value-add and other taxes collected on behalf of third parties. To determine revenue recognition, the Company performs the following five steps: (1) identify the contract with customer; (2) identify the performance obligations in contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation in the contract; and (5) recognize revenues when (or as) the entity satisfies a performance obligation.

 

The Company recognizes revenue as a single performance obligation when it transfers its products to customers, being when the goods are shipped and transfers to a buyer and when performance obligation under contracted sales are completed.

 

Advertising and Promotion

 

All costs associated with advertising and promoting the Company’s goods and services are expensed in the year incurred.

 

 

 

 10 

 

 

Concentrations of Credit Risk

 

The Company’s financial instruments that are exposed to credit risk consist primarily of temporary cash investments and accounts receivable.

 

The Company maintains its cash balances at a large financial institution. At times such balances may exceed federally insured limits. The Company has not experienced any losses in an account. The Company believes it is not exposed to any significant credit risk on cash and had no balances in excess of the $250,000 FDIC limit for the period ended September 30, 2025.

 

For the quarter ended September 30, 2025 and 2024, one and one customer, respectively, accounted for 100% of total revenues earned.

 

The Company’s sole source of expected future revenue consists of the sale of a single live product which requires substantial care. Production risks such as weather, disease and other factors could affect the Company’s ability to realize revenue from its inventory stock.

 

Subsequent Events

 

In preparing these consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through January 14, 2026 , the date the consolidated financial statements were issued. 

 

On December 2, 2025, GHS purchased 12 shares of Series D Preferred Stock under the Securities Purchase Agreement with GHS dated September 18, 2025 (the “September 2025 SPA”).

 

Net Loss Per Share

 

Basic net loss per share is calculated by dividing the net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by using the weighted-average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the dilutive potential shares of common stock had been issued. The dilutive effect of the Company is reflected in diluted net loss per share by application of the treasury stock method. The dilutive securities are excluded from the computation of diluted net loss per share when net loss is recorded for the period as their effect would be anti-dilutive.

 

NOTE 3 – ACCOUNTS RECEIVABLE

 

On December 11, 2023, the Company entered into an accounts receivable factoring agreement in the amount of $750,000. The agreement calls for 80% with recourse financing on eligible receivables. The amount received for the factored receivables on February 7, 2024, totaled $135,847, of which $0 remains outstanding after factoring fees at September 30, 2025 and $0 at September 30, 2024.

 

NOTE 4 – INVENTORY

 

The inventory at September 30, 2025, consists of shrimp broodstock held for sale, and broodstock held for restocking. Included in this amount is the broodstock cost basis reclassified to shrimp held for sale as those costs are applicable expenditures and charges directly and indirectly incurred in bringing shrimp inventory to its existing condition and location as noted in FASB ASC 330-10-30. Although, these animals will eventually come to end of life, their costs are considered part of the necessary costs to birthing and raising shrimp held for sale.

 

Just prior to harvest, the Company segregates and retains selected premium shrimp to become broodstock for the following shrimp harvest cycle. Upon identification and segregation, the selected animals are transferred from outdoor ponds to specialized indoor tanks. These tanks are highly regulated with respect to temperature, lighting and salinity levels. Costs allocated to broodstock animals at September 30, 2025 and September 30, 2024 totaled $54,869 and $210,000, respectively.

 

 

 

 11 

 

 

The number of broodstock was maintained at 4,415 in the year ended December 31, 2024 to the current reporting period of September 30, 2025.

 

Total inventory is as follows at September 30, 2025 and 2024:

      
   2025  2024
Held for Sale          
Shrimp  $0   $12,234 
Broodstock   284,028    0 
Total Held for Sale   284,028    12,234 
Broodstock - Restocking   54,869    210,000 
           
Total inventory  $338,898   $222,234 

 

NOTE 5 – PROPERTY AND EQUIPMENT

 

As of September 30, 2025, and September 30, 2024, the Company had the following property and equipment:

      
   September 30,  September 30,
   2025  2024
Autos and trucks  $9,179   $26,345 
Building and improvements   668,289    668,289 
Farm equipment   348,949    434,598 
Other equipment   85,332    646,067 
    1,111,750    1,775,299 
Less: accumulated depreciation   (471,429)   (547,287)
    640,321    1,228,012 
Land   126,243    6,126,242 
           
Net property and equipment  $766,564   $7,354,254 

  

 

 

 12 

 

 

NOTE 6 –NOTES PAYABLE

 

Notes payable as of September 30, 2025 and September 30, 2024, consisted of the following:

 

          
   September 30,  September 30,
   2025  2024
Note to an entity by the former owner of farm property, interest at 6.00%, due in monthly installments of $38,687 including interest, secured by real property, due in 2039  $0   $4,707,902 
           
Promissory Note to 1800 Diagonal, a commercial lender, with a one-time interest of 13%, due in four installments beginning August 30, 2024, and a due in total by November 30, 2024, Original Discount 18,600   52,253    93,000 
           
Promissory Note to 1800 Diagonal, a commercial lender, with a one-time interest of 13%, due in four installments beginning August 30, 2024, and a due in total by November 30, 2024, Original Discount 18,600   67,400    0 
           
Secured Note to Arcadia Funding, LLC , a commercial Lender, accrued fixed interest at the rate of $12,500/ month, secured by real property, due December 16, 2024   350,000    0 
           
Note to a bank, interest at 3.75%, due in monthly installments of $719.02 including interest, secured by real property, due in 2050   146,875    148,404 
    616,528    4,949,306 
Less Current Portion   (676,577)   (562,063)
           
Net Long-Term Debt  $(60,049)  $4,387,243 

 

The estimated notes payable maturities as of September 30, 2025 are as follows:

   
31-Dec-24  $676,577 
31-Dec-25   0 
31-Dec-26   0 
30-Dec-27   0 
31-Dec-28   0 
Thereafter   0 
      
Total notes payable  $676,577 

 

In February 2024, the Company signed an unsecured promissory note with a lender for $111,600, bearing one-time interest at the rate of 13%, and maturing on four dates beginning on August 2024 and ending on November 2024. The proceeds of this note were issued with an original issue discount of $18,600, yielding net proceeds of $93,000. Upon full maturity, the Company will have paid a total of $126,108 of principal and interest on this note.

 

 

 

 13 

 

 

In May 2024, the Company signed a Secured Promissory Note with a lender for $350,000 bearing fixed interest at the rate of $12,500 per month with maturity date December 2024. The Secured Promissory Note requires monthly interest payments only commencing in June 2024. Principal amount along any accrued but unpaid interest should be paid at maturity date. The note is secured by property owned by the Company and trustee by Travis L. Bence or John R. Bailey.

 

On December 13, 2024, due to a note holder recording a deed in lieu foreclosure, on December 2nd, 2024, TAA filed for Chapter 11 bankruptcy protection under the United States Bankruptcy Code, in the United States Bankruptcy Court for the Southern District of Texas (Case # 24-10217). TAA voluntarily filed for Chapter 11 Bankruptcy to protect the assets of the company (shrimp broodstock and key property, plant, and equipment) due to threats being made by the former farm note holder (Kings Aqua Farm LLC) in which TAA operated on. On December 2, 2024, Kings Aqua Farm LLC filed a Deed in Lieu (“DIL”) of Foreclosure due to non-payment by Trans American Aquaculture. The land was conveyed back to Kings Aqua Farm because of the DIL filing and as such the total debt was extinguished. Over the next two weeks, various threats were made by Kings Aqua Farm on the assets of TAA, which are paramount to the survival and future of the company. To protect those key assets and any future business, TAA elected to file a voluntary Chapter 11 Bankruptcy.

 

On October 28, 2025, the company Chapter 11 Bankruptcy Case was dismissed.

 

In August 2024, the Company signed an unsecured promissory note with a lender for $82,800 bearing one-time interest at the rate of 13%, and maturing on four dates beginning in February 2025 and ending in May 2025. The proceeds of this note were issued with an original issue discount of $13,800 and loan cost $6,000, yielding net proceeds of $63,000. Upon full maturity, the Company will have paid a total of $93,564 of principal and interest on this note.

 

NOTE 7 – RELATED PARTY NOTES PAYABLE

 

As of September 30, 2025, shareholders have loaned the Company approximately $1,646,636 in notes which accrue interest ranging from 12% and 18% per annual period. Maturities between April 1, 2024, and July 1, 2024. Accrued interest related to these notes totaled $900,187 and $561,567 as of September 30, 2025, and September 30, 2024, respectively.

 

NOTE 8 – INCOME TAX

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. 

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be covered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. An allowance has been recorded as of September 30, 2025 due to uncertainty of the realization of deferred tax asset in future periods.

 

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted by the end of the reporting period, and any adjustment to tax payable in respect of previous years.

 

In accordance with FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, included in ASC Topic 740, Income Taxes, the Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. There were no uncertain tax positions that required recognition by the Company. As of the date of these consolidated financial statements, the Company’s federal and various state tax returns will generally remain open for the last three years.

 

 

 

 14 

 

 

The Company’s provision for income taxes attributable to income before income taxes for the periods ended September 30, 2025 and September 30, 2024, consisted of the following:

      
   September 30,  September 30,
   2025  2024
Deferred tax assets related to:          
NOL Carryover  $589,868   $599,828 
Deferred tax liability related to:          
Property and equipment   (18,050)   (7,313)
Deferred tax assets, gross   571,818    592,515 
Less: allowance   (394,890)   (592,515)
           
Net deferred tax asset (liability)  $176,928   $0 
           
Current expense          
Federal  $0   $0 
State   0    0 
           
   $0   $0 
           
Deferred income tax expense (benefit)  $0   $0 

 

NOTE 9 – EQUITY FINANCING AND SECURITIES PURCHASE AGREEMENT

 

Equity Financing Agreement

 

On January 20, 2023, the Company entered into an Equity Financing Agreement (“the EFA”) and Registration Rights Agreement (the “Registration Rights Agreement”) with GHS Investments, LLC, pursuant to which GHS agreed to purchase up to $10,000,000 in shares of the Company common stock, from time to time over the course of 24 months after effectiveness of a registration statement on Form S-1 of the underlying shares of the Company’s common stock.

 

The EFA grants the Company the right, to direct GHS to purchase shares of the Company’s common stock on any business day (a “Put”), provided that at least ten trading days (as defined in the EFA) have passed since the closing of the most recent Put. The purchase price of the shares of common stock contained in a Put shall be 80% of the lowest traded price of the Company common stock during the ten consecutive Trading Days preceding the date of the Put notice. In the event The Company up lists to Nasdaq or an equivalent national exchange, the purchase price will be 90%. No Put will be made in an amount less than $10,000 or greater than $500,000 and any single drawdown may not exceed 200% of the average daily trading dollar volume of the Company’s common stock during the ten trading days preceding the Put. In no event is the Company entitled to make a Put or is GHS entitled to purchase and own cumulative shares greater than 4.99% of the Company’s shares of common stock outstanding on such date.

  

The EFA will terminate upon any of the following events: when GHS has purchased an aggregate of $10,000,000 in the common stock of the Company pursuant to the EFA; or on the date that is 24 months from the date of the EFA.

 

Actual sales of shares of common stock to GHS under the EFA will depend on a variety of factors, including, the number of public shares the Company has available for trading on the open market (excluding closely held and restricted stock), market conditions, the trading price of the common stock, the number of shares outstanding, and the Company’s determinations as to the appropriate sources of funding for the Company and its operations. The net proceeds under the EFA to the Company will depend on the frequency and prices at which the Company sells shares of stock to GHS.

 

 

 

 15 

 

 

The Registration Rights Agreement provides that the Company shall (i) use its best efforts to file with the SEC the Registration Statement within 60 calendar days of the date of the Registration Rights Agreement; and (ii) have the Registration Statement declared effective by the SEC within 60 calendar days after the date the Registration Statement is filed with the SEC, but in no event more than calendar 120 days after the Registration Statement is filed.

 

The Company will use the proceeds from the Puts for general corporate and working capital purposes and acquisitions or assets, businesses, or operations or for purposes the Board of Directors deems to be in the best interests of the Company.

 

On February 27, 2024, the Company put 4,615,277 shares of common stock to GHS at a purchase price of $0.00224 under the EFA for net proceeds of $2,106.

 

On May 29, 2024, the Company put 11,683,300 shares of common stock to GHS at the purchase price of $.0012 under EFA for net proceeds of $12,715.

 

On July 30, 2025, the Company entered into an Equity Financing Agreement (“the EFA”) and Registration Rights Agreement (the “Registration Rights Agreement”) with GHS Investments, LLC, pursuant to which GHS agreed to purchase up to $10,000,000 in shares of the Company common stock, from time to time over the course of 24 months after effectiveness of a registration statement on Form S-1 of the underlying shares of the Company’s common stock.

 

The EFA grants the Company the right, to direct GHS to purchase shares of the Company’s common stock on any business day (a “Put”), provided that at least ten trading days (as defined in the EFA) have passed since the closing of the most recent Put. The purchase price of the shares of common stock contained in a Put shall be 80% of the lowest traded price of the Company common stock during the ten consecutive Trading Days preceding the date of the Put notice. In the event The Company up lists to Nasdaq or an equivalent national exchange, the purchase price will be 90%. No Put will be made in an amount less than $5,000 or greater than $500,000 and any single drawdown may not exceed 200% of the average daily trading dollar volume of the Company’s common stock during the ten trading days preceding the Put. In no event is the Company entitled to make a Put or is GHS entitled to purchase and own cumulative shares greater than 4.99% of the Company’s shares of common stock outstanding on such date.

 

The EFA will terminate upon any of the following events: when GHS has purchased an aggregate of $10,000,000 in the common stock of the Company pursuant to the EFA; or on the date that is 24 months from the date of the EFA.

 

Actual sales of shares of common stock to GHS under the EFA will depend on a variety of factors, including, the number of public shares the Company has available for trading on the open market (excluding closely held and restricted stock), market conditions, the trading price of the common stock, the number of shares outstanding, and the Company’s determinations as to the appropriate sources of funding for the Company and its operations. The net proceeds under the EFA to the Company will depend on the frequency and prices at which the Company sells shares of stock to GHS.

 

The Registration Rights Agreement provides that the Company shall (i) use its best efforts to file with the SEC the Registration Statement within 60 calendar days of the date of the Registration Rights Agreement; and (ii) have the Registration Statement declared effective by the SEC within 60 calendar days after the date the Registration Statement is filed with the SEC, but in no event more than calendar 120 days after the Registration Statement is filed.

 

The Company will use the proceeds from the Puts for general corporate and working capital purposes and acquisitions or assets, businesses, or operations or for purposes the Board of Directors deems to be in the best interests of the Company. 

 

 

 

 16 

 

 

Securities Purchase Agreements

 

On January 20, 2023, The Company entered into a Securities Purchase Agreement with GHS (the “GHS SPA”) pursuant to which 250 shares of Series D Preferred Stock for $250,000 were sold to GHS at a price per share of $1,000. In addition, pursuant to the GHS SPA, the Company issued to GHS warrants to purchase 46,296,296 shares of common stock exercisable at $0.005175 per share and terminating on January 20, 2028.

 

On April 18, 2023, the Company entered into an Amended Securities Purchase Agreement with GHS (the “Amended SPA”) pursuant to which the Company sold to GHS 102 shares of Series D Preferred Stock for $102,000 ($1,000 for each share of Series D Preferred Stock). In addition, pursuant to the Amended SPA, the Company issued to GHS warrants to purchase 20,606,061 shares of Common Stock exercisable at $0.00391 per share and terminating on January 20, 2028.

 

On May 22, 2023, the Company entered into an Amended Securities Purchase Agreement with GHS (the “Amended SPA”) pursuant to which the Company sold to GHS 184 shares of Series D Preferred Stock for $184,000 ($1,000 for each share of Series D Preferred Stock). In addition, pursuant to the Amended SPA, the Company issued to GHS warrants to purchase 42,666,667 shares of Common Stock exercisable at $0.00345 per share and terminating on January 20, 2028.

 

On July 6, 2023, the Company entered into an Amended Securities Purchase Agreement with GHS (the “Amended SPA”) pursuant to which the Company sold to GHS 96 shares of Series D Preferred Stock for $96,000 ($1,000 for each share of Series D Preferred Stock). In addition, pursuant to the Amended SPA, the Company issued to GHS warrants to purchase 19,047,620 shares of Common Stock exercisable at $0.004025 per share and terminating on January 20, 2028.

 

On September 26, 2023, the Company entered into a Securities Purchase Agreement with GHS (the “September 2023 SPA”) pursuant to which the Company agreed to sell GHS 151 shares of Series D.

 

Preferred Stock for $146,000 ($1,000 for each share of Series D Preferred Stock and five commitment shares). At the initial closing, GHS purchased 76 shares ($1,000 per share of Series D Preferred Stock) and within 25 calendar days from the initial closing, GHS agreed to purchase 70 shares of Series D Preferred Stock. In addition, pursuant to the September 2023 SPA, the Company issued to GHS warrants to purchase 14,901,961 shares of Common Stock exercisable at $0.003795 per share and terminating on September 26, 2028. On October 12, 2023, GHS purchased the remaining 70 shares of Series D Preferred Stock under the September 2023 SPA. In addition, pursuant to the September 2023 SPA, the Company issued to GHS warrants to purchase 14,705,883 shares of Common Stock exercisable at $0.003795 per share and terminating on October 12, 2028.

 

On March 28, 2025, the Company entered into a Securities Purchase Agreement with GHS (the “March 2025 SPA”) pursuant to which the Company agreed to sell GHS 104 shares of Series D.

 

Preferred Stock for $104,000 ($1,000 for each share of Series D Preferred Stock and ten commitment shares). At the initial closing, GHS purchased 36 shares ($1,000 per share of Series D Preferred Stock). Additional Closings will be for the purchase of Preferred Shares as follows: (a) two (2) separate purchases of fifteen (15) and fifty three (53) shares of Preferred Stock for the purchase price of $15,000 and $53,000, respectively.

 

In addition, pursuant to the March 2025 SPA, the Company issued to GHS warrants to purchase 306,666,667 shares of Common Stock exercisable at $0.000115 per share and terminating on March 28, 2030.

 

On April 2, 2025, GHS purchased 15 shares of Series D Preferred Stock under the March 2025 SPA. 40,350,887 warrants were issued to GHS.

 

On June 18, 2025, GHS purchased 25 shares of Series D Preferred Stock under the March 2025 SPA. 67,251,462 warrants were issued to GHS.

  

 

 

 17 

 

 

During the quarter ended September 30, 2025, the Company recorded an adjustment related to the issuance of its Series C Preferred Stock. The adjustment reflects $283,967 classified as Preferred Series C Stock Payable, representing the value of preferred shares authorized for issuance but not yet physically issued.

 

On September 18, 2025, the Company entered into the September 2025 SPA pursuant to which the Company agreed to sell GHS 63 shares of Series D Preferred Stock for $60,000 ($1,000 for each share of Series D Preferred Stock and ten commitment shares). At the initial closing, GHS purchased 19 shares ($1,000 per share of Series D Preferred Stock). Additional Closings will be for the purchase of Preferred Shares as follows: (a) separate purchases of 44 of Preferred Stock for the purchase price of $44,000.

 

In addition, pursuant to the September 2025 SPA, the Company issued to GHS warrants to purchase 71,250,000 shares of Common Stock exercisable at $0.000345 per share and terminating on September 18, 2030.

 

NOTE 10 – LITIGATION

 

From time to time the Company is involved in lawsuits against the Company involving general liability or various contractual matters. In the opinion of the Company’s management, the potential claims against the Company not covered by insurance resulting from such litigation will not materially affect the financial position of the Company.

 

NOTE 11 - GOING CONCERN

 

The Company follows FASB ASU 2014-10 – Development Stage Entities because its principal operations have commenced, but there has been no significant revenue therefrom. To date, the Company’s activities since inception have consisted principally of acquiring property, equipment, and other operating assets, raising capital, starting up production, recruiting and training personnel and raising capital.

 

The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan as well as continuing to develop its brood stock in order to fulfill recently signed contracts. The financial statements do not include any adjustments that might be necessary if the business plan cannot be implemented or if additional capital cannot be raised, either of which could result in the Company not being able to continue as a going concern.

 

The Company is in the process of raising additional capital to support the completion of the developmental stage activities and ramp up ongoing full shrimp harvest cycles and establish its customer base. Therefore, the Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s current technology.

 

 

 

 

 

 

 

 

 

 18 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations contain certain forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events; are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements. We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.

 

Critical Accounting Policies

 

The following discussions are based upon our financial statements and accompanying notes, which have been prepared in accordance with GAAP Financial Measures of the United States.

 

The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingencies. We continually evaluate the accounting policies and estimates used to prepare the financial statements. We base our estimates on historical experiences and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management.

 

Accounting for Our Shrimp Inventory

 

Our inventory of shrimp is divided into shrimp held for sale and broodstock shrimp. Broodstock are shrimp that are used for breeding purposes; selected for their genetic, disease-free and size attributes they can be more valuable than shrimp held for sale. We collect broodstock from the biomass just before the harvest and segregate them from the shrimp that will be harvested and sold. Broodstock, because of their higher value, may be sold to other shrimp farmers in the United States and overseas. We also keep a number of broodstock for our own restocking purposes. So, during the year, our inventory can consist of shrimp held for sale, broodstock held for sale and broodstock used for restocking purposes.

 

Shrimp farming is a seasonal business. On a calendar year basis, we typically use the broodstock to breed our larvae shrimp during the first quarter so that by spring the shrimp are held in large post-larvae tanks for development. Later, in early summer, the shrimp are transferred to ponds where they complete the grow out process over the next five to nine months. This can vary if we have more than one cycle of shrimp. Grow out may begin in the second in the second quarter, with a second cycle grow out beginning in early summer. The first harvest cycle can occur in early fall with the second harvest cycle occurring in November or December. During 2023, we had one cycle and harvest occurred in early November 2023. During 2024, we did not stock, nor did we have a harvest. In 2025, we have not stocked the ponds or had a harvest. At this time, we are only maintaining the broodstock lines. We plan to refresh the lines in 1Q26, which will depend on investment funds raised.

 

Our shrimp inventory is valued at lower of cost or the net realizable value on a first-in, first-out basis.

 

The inventory at September 30, 2025 consists of live broodstock animals. Included in this amount are costs and charges directly and indirectly incurred in bringing shrimp inventory to its existing condition and location as noted in FASB ASC 330-10-30.

 

 

 

 19 

 

 

At September 30, 2025, the broodstock shrimp for the 2025 harvest had been identified and segregated from consumable shrimp in outdoor ponds to indoor tanks. The table below summarizes inventory at September 30, 2025 and 2024.

 

   September 30,
2025
  September 30,
2024
Held for Sale          
Shrimp  $0   $12,234 
Broodstock   284,028    0 
Total Held for Sale   284,028    12,234 
Broodstock - Restocking   54,869    210,000 
           
Total inventory  $338,898   $222,234 

 

At September 30, 2025, approximately 4,415 animals of broodstock will be used to populate our post larval development in 2026. The cost of the broodstock was reclassified to broodstock held for restocking on a pro rata basis of cost per pound of the total biomass of shrimp held for sale. Subsequent costs will be allocated in accordance with ASC 330-10-30.

 

Business Overview

 

Founded in 2017, we are a leading aquaculture company that provides premium quality, farm-raised pacific white shrimp, 100% free of antibiotics and hormones, to the U.S. domestic seafood market. We believe we are a leading aquaculture company due to Best Aquaculture Practices (“BAP”) guidelines,1 considering the rarity of the standards in the U.S. Although we are not currently in full compliance with BAP guidelines, we are working towards full compliance. At the moment, we adhere to BAP guidelines as part of our operating and production model. Grown at our 1,880-acre farm located in Rio Hondo, Texas, on the largest scale aquaculture farm in the U.S., our shrimp are meticulously raised to exceed in line with industry best practices according to BAP guidelines2 using only authentic, sustainable practices. Within our controlled facility, each harvest is responsibly raised and cultivated onsite with minimal ecological footprint, promising our customers a superior product developed from the highest standard of care.

 

We have and will continue to utilize superior genetic linage broodstock for cultivation of own post larvae in our onsite genetics, maturation and hatchery facilities. These facilities allow us to continually develop animals with increasing growth rates, lower mortality, and stronger disease resistance. We began formal production runs in 2018 and to date have produced almost one million lbs. of shrimp for consumption.

 

Recent trends in the shrimp industry, including that, according to preliminary 2023 data from the National Marine Fisheries Service, shrimp prices have dropped as much as 44% since 2022.3 Our business, prospects, revenues, profitability, and future growth are highly dependent upon the prices of and demand for shrimp. Our ability to borrow and to obtain additional capital on attractive terms is also substantially dependent upon shrimp prices. These prices have been and are likely to continue to be extremely volatile for seasonal, cyclical, and other reasons. Any substantial or extended decline in the price of shrimp will have a material adverse effect on our financing capacity and our prospects for commencing and sustaining any economic commercial production. In addition, increased availability of imported shrimp can affect our business by lowering commodity prices. This could reduce the value of inventories, held both by us and by our customers, and cause many of our customers to reduce their orders for new products until they can dispose of their higher-cost inventories.

 

Going Concern Uncertainty

 

As shown in the accompanying financial statements, during the three-months ended September 30, 2025, we reported a net loss of $171,642. As of September 30, 2025, our current liabilities exceeded its current assets by $4,379,486. As of September 30, 2025, we had $509 in cash. During the year ended December 31, 2024, we reported a net loss of $2,808,894. As of December 31, 2024, our current liabilities exceeded our current assets by $3,351,602. As of December 31, 2024, we had $0 cash.

 

_____________

 

1 https://www.bapcertification.org/Downloadables/pdf/BAP%20-%20BAP%20Farm%20Standard%20-%20Issue%203.1%20-%2007-February-2023.pdf

2 https://www.bapcertification.org/Downloadables/pdf/BAP%20-%20BAP%20Farm%20Standard%20-%20Issue%203.1%20-%2007-February-2023.pdf

3 https://civileats.com/2023/06/20/cheap-imports-leave-us-shrimpers-struggling-to-compete/#:~:text=The%20U.S.%20Food%20and%20Drug,before%20entering

%20the%20U.S.%20market

 

 

 

 20 

 

 

We will require additional funding to finance the growth of our operations and achieve our strategic objectives. These factors, as relative to capital raising activities, create doubt as to our ability to continue as a going concern. We are seeking to raise additional capital and are targeting strategic partners to accelerate the sales and marketing of our products and begin generating revenues. Our ability to continue as a going concern is dependent upon the success of future capital offerings or alternative financing arrangements, expansion of our operations and generating sales. The accompanying financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. Management is actively pursuing additional sources of financing sufficient to generate enough cash flow to fund its operations; however, management cannot make any assurances that such financing will be secured.

 

Results of Operations for the Three-Months Ended September 30, 2025 and 2024

 

Revenues

 

For the three-months ended September 30, 2025, total revenues were $0 compared to $0 for the same period in 2024, a decrease of $0 or 0%. This decrease was related to the company not having shrimp for sale and only maintaining the broodstock for future genetic development and stocking.

 

Cost of Goods Sold and Gross Profit

 

For the three-months ended September 30, 2025, cost of goods sold was $0 compared to $196,552 for the same period in 2024, a decrease of $196,552 or 100%. This was the result of not producing and harvesting or selling shrimp during the current three months ended September 30, 2025.

 

The gross profit for the three-months ended September 30, 2025 was $0 for an operating profit of $0 compared to a gross profit margin of $-196,552 for the same period in 2024.

 

Operating Expenses

 

General and administrative expenses for three-months ended September 30, 2025 decreased by $129,854, or 61%, to $83,396 from $213,250 for the three-months ended September 30, 2024. This decrease in expenses resulted from lower legal and professional fees and accrued payroll wages.

 

Other Income (Expense)

 

For the three-months ended September 30, 2025, we had interest expenses of $88,246 compared to interest expenses of $175,836 for the same period in 2024, a decrease in interest expense of $87,590. This decrease in interest expense was due primarily to reduction in interest related to the farm note.

 

Net Income (Loss)

 

As a result of the above, we reported a net loss of $171,642 for the three-months ended September 30, 2025 compared to a net loss of $575,325 for the three-months ended September 30, 2024.

 

Results of Operations for the Nine-Months Ended September 30, 2025 and 2024

 

Revenues

 

For the nine-months ended September 30, 2025, total revenues were $0 compared to $315,145 for the same period in 2024, a decrease of $315,145 or 100%. This decrease was related to the company not having shrimp for sale and only maintaining the broodstock for future genetic development and stocking.

 

 

 

 21 

 

 

Cost of Goods Sold and Gross Profit

 

For the nine-months ended September 30, 2025, cost of goods sold was $0 compared to $419,851 for the same period in 2024, a decrease of $419,851 or 100%. This was the result of not producing and harvesting or selling shrimp during the current three months ended September 30, 2025.

 

The gross profit for the nine-months ended September 30, 2025 was $0 for an operating profit of 0% compared to a gross profit margin of $-104,706 for the same period in 2024.

 

Operating Expenses

 

General and administrative expenses for nine-months ended September 30, 2025 decreased by $268,276, or 50%, to $266,357 from $534,633 for the nine-months ended September 30, 2024. This reduction in expenses resulted from lower legal and professional fees and payroll wages.

 

Other Income (Expense)

 

For the nine-months ended September 30, 2025, we had interest expenses of $215,528 compared to interest expenses of $449,356 for the same period in 2024, a decrease in interest expense of $233,828. This decrease in interest expense was due primarily to reduction in interest related to the farm note.

 

Net Income (Loss)

 

As a result of the above, we reported a net loss of $489,387 for the nine-months ended September 30, 2025 compared to a net loss of $1,143,656 for the nine-months ended September 30, 2024.

 

Liquidity and Capital Resources

 

As of September 30, 2025, we had a cash balance of $509, compared to a balance of $0 at September 30, 2024. We currently do not have sufficient cash to fund our operations for the next 12 months and we will require working capital to complete development and production, testing and marketing of our products and to pay for ongoing operating expenses. We anticipate adding management positions for corporate development and the corresponding operations of the Company, but this will not occur prior to obtaining additional capital. Currently, competitively priced loans from banks or other lending sources for lines of credit or similar short-term borrowings are not available to us. We have been able to raise working capital to fund operations through the issuances of convertible preferred stock to GHS, factoring our receivables, and borrowing funds from employees of the Company. As of September 30, 2025, our current liabilities exceeded our current assets by $4,379,486 as compared to September 30, 2024, when current liabilities exceeded current assets by $3,351,602 , an increase of $1,027,884.

 

The Company is also a party to an SBA Loan through a bank in the original amount of $150,000 bearing interest at 3.75% per annum, due in 2050, yielding a monthly payment amount of $731.

 

Liquidity is also affected by notes to our shareholders. At September 30, 2025, shareholders have loaned the Company approximately $1,646,636 which notes accrue interest at ranging from 12.0% to 18% per annum and were due September 30, 2024. The Company extended this due date to July 1, 2024, and plans to extend them again into 2026. Current discussions with noteholders are underway and we expect the noteholders to agree to this extension, but to date, no extensions have been finalized or approved.

 

 

 

 22 

 

 

In February 2024, the Company signed an unsecured promissory note with a lender for $111,600, bearing one-time interest at the rate of 13%, and maturing on four dates beginning on August 30, 2024 and ending on November 30, 2024. The proceeds of this note were issued with an original issue discount of $18,600, yielding net proceeds of $88,000. Upon full maturity, the Company will have paid a total of $126,108 of principal and interest on this note.

 

Cash Flows from Operating Activities

 

During the three-months ended September 30, 2025, net cash used in operating activities was $-54,305, due mainly to a net loss of $171,642, an increase in accounts payable of $57,086 mostly of payroll liabilities, and an increase of $88,246 in accrued interest. By comparison, during the three-months ended September 30, 2024, net cash used in operating activities was $389,780, due mainly to a net loss of $568,332, payroll liabilities, offset by an increase of $216,203 in accrued interest.

 

During the nine-months ended September 30, 2025, net cash used in operating activities was $-771,113, due mainly to a net loss of $-489,387, an increase in accounts payable of $835,244 mostly of payroll liabilities, professional services and reclassification of notes payment from related parties. By comparison, during the nine-months ended September 30, 2024, net cash used in operating activities was $442,196 due mainly to a net loss of $1,143,656, increase in accounts payable and accrued expense of $613,243 due to increased operations, and increase in accrued interest expense due mainly to falling into arrears on the note payable covering our farm property and increased interest expense on notes payable to shareholders.

 

Cash Flows from Investing Activities

 

During the three-months ended September 30, 2025, we had $10,616 net cash used in investing activities. During the three-months ended September 30, 2024, we had $0 net cash used in investing activities.

 

During the nine-months ended September 30, 2025, we had $21,232 net cash used in investing activities. During the nine-months ended September 30, 2024, we had $7,494 net cash used in investing activities.

 

Cash Flows from Financing Activities

 

During the three-months ended September 30, 2025, net cash provided by financing activities was $44,000 which was mainly comprised of proceeds from the purchase of Preferred Series D Shares of $44,000. During the three-months ended September 30, 2024, net cash provided by financing activities was $395,397 which was mainly comprised of proceeds from notes payable of $443,000, offset by payments due related parties of $70,850.

 

During the nine-months ended September 30, 2025, net cash provided by financing activities was $743,696 which was mainly comprised of proceeds from the purchase of Preferred Series D Shares of $117 and reclassification of related party notes payable. During the nine-months ended September 30, 2024, net cash provided by financing activities was $428,102 which was mainly comprised of proceeds from notes payable of $506,000, offset by payments due to shareholders of $74,375, and notes payable of $74,243. During the nine-months ended September 30, 2023, net cash provided by financing activities was $908,667 which was mainly comprised of proceeds from $958,000 from issued Series D Preferred Stock to GHS, offset by $116,488 in payments on related party notes and $56,258 in notes payable as well as proceeds from shareholder notes of $123,700.

 

 

 

 23 

 

 

Factors That May Affect Future Results

 

Management’s Discussion and Analysis contains information based on management’s beliefs and forward-looking statements that involve several risks, uncertainties, and assumptions. There can be no assurance that actual results will not differ materially from the forward-looking statements as a result of various factors, including but not limited to, our ability to obtain the equity/debt funding or borrowings necessary to produce, market and launch our products, our ability to successfully serially produce and market our products; our success establishing and maintaining production lines; the acceptance of our products by customers; our continued ability to pay operating costs; our ability to meet demand for our products; the amount and nature of competition from our competitors; the effects of technological changes on products and product demand; and our ability to successfully adapt to market forces and technological demands of our customers.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

 

Recent Accounting Pronouncements

 

We have provided a discussion of recent accounting pronouncements in NOTE 2 to the Quarterly Consolidated Financial Statements for September 30, 2025 and 2024.

  

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a smaller reporting company, the Company has elected not to provide the disclosure required by this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures 

 

We have established disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and, as such, is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, Adam Thomas who serves as our principal executive officer and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Mr. Thomas has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, as of September 30, 2025. Based on his evaluation, Mr. Thomas concluded that, due to a material weakness in our internal control over financial reporting, our disclosure controls and procedures were not effective as of September 30, 2025. In light of the material weakness in internal control over financial reporting, we completed substantive procedures, including validating the completeness and accuracy of the underlying data used for accounting prior to filing this Form 10-Q.

 

These additional procedures have allowed us to conclude that, notwithstanding the material weakness in our internal control over financial reporting, the consolidated financial statements included in this Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.

 

Changes in Internal Control Over Financial Reporting

 

There has been no change in the Company’s internal control over financial reporting, as defined in Rules 13a-15(f) of the Exchange Act, during our quarter ended September 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

  

 

 

 24 

 

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

On October 28, 2025, the company Chapter 11 Bankruptcy Case was dismissed.

 

Item 5. Other Information.

 

During the quarter ended September 30, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

Item 6. Exhibits

 

SEC Ref. No. Title of Document
10.1* Equity Financing Agreement  dated July 30, 2025 with GHS Investments, LLC
10.2* Registration Rights Agreement  dated July 30, 2025 with GHS Investments, LLC
10.3* Securities Purchase Agreement dated September 17, 2025 with GHS Investments, LLC
10.4* Warrant Agreement dated September 17, 2025 with GHS Investments, LLC
31.1* Rule 13a-14(a) Certification by Principal Executive Officer
31.2* Rule 13a-14(a) Certification by Principal Financial and Accounting Officer
32.1** Section 1350 Certification of Principal Executive Officer and Principal Financial and Accounting Officer
101.INS* XBRL Instance Document
101.SCH* XBRL Taxonomy Extension Schema Document
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document
104* Cover Page Interactive Data File (formatted in Inline XBRL, and included in exhibit 101).

 

*Filed with this Report.

**Furnished with this Report.

 

 

 

 

 25 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TRANS AMERICAN AQUACULTURE, INC.
     
January 14, 2026 By: /s/ Adam Thomas
    Adam Thomas
    Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 26 

 

FAQ

How did Trans American Aquaculture (GRPS) perform financially in Q3 2025?

For the quarter ended September 30, 2025, Trans American Aquaculture reported total revenues of $0 and a net loss of $171,642, compared with a net loss of $575,325 for the same period in 2024. The improvement mainly reflected lower cost of goods sold and reduced general and administrative expenses, but the business still generated no sales and continued to incur losses.

What were Trans American Aquaculture’s results for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, the company recorded revenues of $0, down from $315,145 in the prior‑year period, as it did not produce or harvest shrimp and only maintained broodstock. The net loss narrowed to $489,387 from $1,143,656, reflecting lower production costs, reduced legal and professional fees, and lower interest expense related to a farm note.

What is the liquidity position of Trans American Aquaculture (GRPS) as of September 30, 2025?

As of September 30, 2025, the company had cash of $509 and current assets of $340,123 against current liabilities of $4,719,609, resulting in a working capital deficit of $4,379,486. Total assets were $1,106,686, while stockholders’ deficit was $3,758,603. Management states that additional capital is required to fund operations and support its shrimp production plans.

Does Trans American Aquaculture’s Q3 2025 10-Q raise going concern issues?

Yes. The filing includes a going concern note explaining that the company has incurred recurring losses, has minimal cash, and a substantial working capital deficit. Its ability to continue as a going concern depends on raising additional capital, successfully ramping shrimp production, and establishing a customer base. The financial statements do not include adjustments that might be necessary if it cannot continue as a going concern.

What equity and financing arrangements does Trans American Aquaculture have with GHS Investments?

The company has entered into multiple arrangements with GHS Investments, LLC. Equity Financing Agreements dated January 20, 2023 and July 30, 2025 each allow GHS to purchase up to $10,000,000 of common stock over 24 months, at a discount to market, subject to a 4.99% ownership cap. Several Securities Purchase Agreements since 2023 also provided cash in exchange for Series D Preferred Stock and large warrant issuances, including 306,666,667 warrants at a $0.000115 exercise price under a March 28, 2025 agreement and 71,250,000 warrants at $0.000345 under a September 18, 2025 agreement.

What is the status of Trans American Aquaculture’s bankruptcy case mentioned in the Q3 2025 10-Q?

The company’s operating subsidiary filed for Chapter 11 bankruptcy protection on December 13, 2024 after a deed in lieu of foreclosure transferred its farm property back to the former note holder. The filing states that this Chapter 11 case was dismissed on October 28, 2025. Despite the dismissal, the company continues to highlight significant financial risk and going concern uncertainty.

How many Trans American Aquaculture (GRPS) common shares are outstanding and what is the capital structure?

Common stock had 6,000,000,000 shares authorized and 1,805,926,955 shares issued and outstanding as of both September 30, 2025 and January 14, 2026, with a par value of $0.000001 per share. The company also has several preferred series outstanding, including Series A, B, C, and D, and has issued significant additional paid‑in capital and warrants through securities purchase agreements, contributing to a total stockholders’ deficit of $3,758,603 at September 30, 2025.

Gold River Prod

OTC:GRPS

GRPS Rankings

GRPS Latest News

GRPS Latest SEC Filings

GRPS Stock Data

549.66k
1.24B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Dallas